Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and18F-fluoride PET/CT

Journal of Nuclear Medicine

Volumn 49, Issue 3, 2008, Pages 414-421

  Hsu, Wellington K ^a   Virk, Mandeep S ^a   Feeley, Brian T ^a   Stout, David B ^a   Chatziioannou, Arion F ^a   Lieberman, Jay R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Osteoblastic lesion; Osteolytic lesion; PET CT; Prostate cancer; Small animal imaging

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; BONE ATROPHY; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY; SEVERE COMBINED IMMUNODEFICIENCY; SOFT TISSUE TUMOR;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MICE; MICE, SCID; OSTEOLYSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 40449093973     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.045666     Document Type: Article

References (41)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49(1):8-31.
2. Koutsilieris M, Rabbani SA, Bennett HP, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest. 1987;80:941-946.
3. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998;17:331-336.
4. Kasper S, Smith JA Jr. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol. 2004;172:12-19.
5. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. Cancer. 2003;97(3 suppl):748-757.
6. Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia. 1999;1:303-310.
7. Herschman HR. Micro-PET imaging and small animal models of disease. Curr Opin Immunol. 2003;15:378-384.
8. Chatziioannou AF, Cherry SR, Shao Y, et al. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med. 1999;40:1164-1175.
9. Gambhir SS, Herschman HR, Cherry SR, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2000;2:118-138.
10. Kornblum HI, Araujo DM, Annala AJ, Tatsukawa KJ, Phelps ME, Cherry SR. In vivo imaging of neuronal activation and plasticity in the rat brain by high resolution positron emission tomography (microPET). Nat Biotechnol. 2000;18:655-660.
11. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332-334.
12. Narita N, Kato K, Nakagaki H, Ohno N, Kameyama Y, Weatherell JA. Distribution of fluoride concentration in the rat's bone. Calcif Tissue Int. 1990;46:200-204.
13. 11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem. 2004;12:2887-2893.
14. 18F-fluoride PET. Eur J Nucl Med Mol Imaging. 2004;31:1291-1298.
15. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834.
16. O'Sullivan F, Roy S, O'Sullivan J, Vernon C, Eary J. Incorporation of tumor shape into an assessment of spatial heterogeneity for human sarcomas imaged with FDG-PET. Biostatistics. 2005;6:293-301.
17. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210-3216.
18. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2002;4:99-104.
19. Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999;59:5030-5036.
20. Gamradt SC, Feeley BT, Liu NQ, et al. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res. 2005;25(1A):107-115.
21. Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res. 2005;23(6):1475-1483.
22. Lee Y, Schwarz E, Davies M, et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res. 2003;21:62-72.
23. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17:16-23.
24. Wetterwald A, van der Pluijm G, Que I, et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol. 2002;160:1143-1153.
25. Plonowski A, Schally AV, Varga JL, et al. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate. 2000;44:172-180.
26. Wieland B, Bida G, Padgett H, Go H. Current status of CTI target systems for the production of PET radiochemicals [abstract]. In: Proceedings of the 3rd Workshop on Targetry and Target Chemistry; June 19-23, 1989; Vancouver, British Columbia, Canada.
27. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
28. Chow PL, Stout DB, Komisopoulou E, Chatziioannou AF. A method of image registration for small animal, multi-modality imaging. Phys Med Biol. 2006;51:379-390.
29. Stout D, Chow P, Gustilo A, Grubwieser S, Chatziioannou A. Multimodality isolated bed system for mouse imaging experiments [abstract]. Mol Imaging Biol. 2003;5(suppl 3):128-129.
30. Chatziioannou A, Qi J, Moore A, et al. Comparison of 3-D maximum a posteriori and filtered backprojection algorithms for high-resolution animal imaging with microPET. IEEE Trans Med Imaging. 2000;19:507-512.
31. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
32. Tai C, Chatziioannou A, Siegel S, et al. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol. 2001;46:1845-1862.
33. Piert M, Zittel TT, Becker GA, et al. Assessment of porcine bone metabolism by dynamic. J Nucl Med. 2001;42:1091-1100.
34. 18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949-955.
35. Machtens S, Boerner AR, Hofmann M, Knapp WH, Jonas U. Urologe A. 2004;43:1397-1409.
36. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751-756.
37. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol. 2002;41:425-429.
38. Bylund A, Zhang JX, Bergh A, et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate. 2000;42:304-314.
39. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
40. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med. 2001;28:99-103.
41. Taschereau R, Chow PL, Chatziioannou A. Monte Carlo simulations of dose from microCT imaging procedures in a realistic mouse phantom. Med Phys. 2006;33:216-224.